Chemical formula: C₂₃H₂₈ClN₃O₅S Molecular mass: 494.004 g/mol PubChem compound: 3488
Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BB01 | Glibenclamide | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BB Sulfonamides, urea derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| GLIBESYN Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| AMGLIDIA Oral suspension | European Medicines Agency (EU) | MPI, EU: SmPC |
Glibenclamide is an active ingredient of these brands:
United States (US)Albania (AL)Australia (AU)Austria (AT)Croatia (HR)Ecuador (EC)
Estonia (EE)France (FR)
Germany (DE)Hong Kong (HK)
Ireland (IE)Israel (IL)Japan (JP)Lithuania (LT)Mexico (MX)
Netherlands (NL)
New Zealand (NZ)Nigeria (NG)Poland (PL)Romania (RO)
Singapore (SG)
South Africa (ZA)
Tunisia (TN)
United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
